Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 2, 2013 (13 years ago)

Methotrexate 25mg/mL Injectable

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Methotrexate 25mg/mL Injectable, 10 mL vials, Compounded by The Compounding Shop, St. Petersburg, FL

Drug: Methotrexate

Recalling firm
The Compounding Shop, INC.
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-548-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Methotrexate recalls

See all
Class III · Low risk

Methotrexate Tablets

Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.

Completed Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 69238-1423-1 D-0629-2024
Class III · Low risk

Methotrexate Tablets

Failed Tablet/Capsule Specifications: Tablets were observed to have an unsmooth surface with two tablets demonstrating illegible tablet identification and scoring.

Ongoing Failed specification West-Ward Columbus Inc D-0066-2024
Class II · Moderate risk

Methotrexate Injection

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 61703-350-38 D-0553-2021

Other recalls by The Compounding Shop, INC.

All 2013 recalls
Class II · Moderate risk

Praziquantel 56.8 mg

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination The Compounding Shop, INC. D-570-2013
Class II · Moderate risk

Carnosine 5% Opth drop

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination The Compounding Shop, INC. D-569-2013